Inventor · disambiguated record
Laurence J.N. Cooper
Also filed as: COOPER LAURENCE · COOPER LAURENCE J · COOPER LAURENCE J N
12 granted patents·30 pending applications·169 citations·filing 2004–2024
89Inventor score
Files withUNIV TEXAS21HOPE CITY9SANGAMO THERAPEUTICS INC4SANGAMO BIOSCIENCES INC2COLLINGWOOD TREVOR1
Top patents by PatentIndex Score
42 records- 0198US8945868B2Methods and compositions for modification of a HLA locusCOLLINGWOOD TREVOR·Filed 2011·Granted Feb 3, 2015·122 cites·9 claims
- 0293US10072062B2Methods and compositions for modification of a HLA locusSANGAMO BIOSCIENCES INC·Filed 2015·Granted Sep 11, 2018·11 cites·11 claims
- 0392US10125193B2Chimeric antigen receptors and methods of makingUNIV TEXAS·Filed 2015·Granted Nov 13, 2018·23 cites·7 claims
- 0491US10883094B2Transposase polypeptides and uses thereofUNIV TEXAS·Filed 2020·Granted Jan 5, 2021·3 cites·19 claims
- 0587US10570382B2Transposase polypeptides and uses thereofUNIV TEXAS·Filed 2016·Granted Feb 25, 2020·8 cites·20 claims
- 0684US10858416B2Methods and compositions for modification of a HLA locusSANGAMO THERAPEUTICS INC·Filed 2018·Granted Dec 8, 2020·1 cites·9 claims
- 0781US2025002579A1Chimeric antigen receptors and methods of makingUNIV TEXAS·Filed 2024·Application pending·0 cites
- 0880US2024156929A1Human application of engineered chimeric antigen receptor (car) t-cellsUNIV TEXAS·Filed 2023·Application pending·0 cites
- 0979US12116604B2Transposase polypeptides and uses thereofUNIV TEXAS·Filed 2022·Granted Oct 15, 2024·0 cites·25 claims
- 1075US2009191172A1Method of Controlling Administration of Cancer AntigenHOPE CITY·Filed 2009·Application pending·0 cites
- 1173US2023312675A1Chimeric antigen receptors (car) and methods for making and using the sameUNIV TEXAS·Filed 2023·Application pending·0 cites
- 1273US2021145873A1Method of Controlling Administration of Cancer AntigenHOPE CITY·Filed 2020·Application pending·0 cites
- 1373US2015297640A1Method of Controlling Administration of Cancer AntigenHOPE CITY·Filed 2014·Application pending·0 cites
- 1472US12065490B2Chimeric antigen receptors and methods of makingUNIV TEXAS·Filed 2021·Granted Aug 20, 2024·0 cites·20 claims
- 1571US11492604B2Transposase polypeptides and uses thereofUNIV TEXAS·Filed 2020·Granted Nov 8, 2022·0 cites·10 claims
- 1671US2018280433A1Method of Controlling Administration of Cancer AntigenHOPE CITY·Filed 2018·Application pending·0 cites
- 1770US10633445B2T-cell receptor (TCR)-binding antibodies and uses thereofUNIV TEXAS·Filed 2016·Granted Apr 28, 2020·1 cites·23 claims
- 1870US2007166327A1Mammalian antigen-presenting T cells and bi-specific T cellsHOPE CITY·Filed 2007·Application pending·0 cites
- 1970US2021054046A1Methods and compositions for modification of a hla locusSANGAMO THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2068US2022202858A1Methods and compositions for modification of hlaSANGAMO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2165US12410232B2Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptorUNIV PENNSYLVANIA·Filed 2021·Granted Sep 9, 2025·0 cites·8 claims
- 2264US2005129671A1Mammalian antigen-presenting T cells and bi-specific T cellsHOPE CITY·Filed 2004·Application pending·0 cites
- 2363US2021187028A1Polyclonal gamma delta t cells for immunotherapyUNIV TEXAS·Filed 2020·Application pending·0 cites
- 2463US2020102366A1Chimeric antigen receptors (car) and methods for making and using the sameUNIV TEXAS·Filed 2019·Application pending·0 cites
- 2562US2013149337A1Method of controlling administration of cancer antigenCOOPER LAURENCE·Filed 2011·Application pending·0 cites
- 2660US2018200299A1Polyclonal gamma delta t cells for immunotherapyUNIV TEXAS·Filed 2018·Application pending·0 cites
- 2760US2022072041A1Gene modified immune effector cells and engineered cells for expansion of immune effector cellsUNIV TEXAS·Filed 2021·Application pending·0 cites
- 2857US2019085079A1Chimeric antigen receptors and methods of makingUNIV TEXAS·Filed 2018·Application pending·0 cites
- 2956US2020247867A1Chimeric antigen receptors (car) to selectively target protein complexesUNIV TEXAS·Filed 2020·Application pending·0 cites
- 3056US2015037304A1Methods and compositions for modification of hlaSANGAMO BIOSCIENCES INC·Filed 2014·Application pending·0 cites
- 3154US2007036773A1Generation and application of universal T cells for B-ALLHOPE CITY·Filed 2006·Application pending·0 cites
- 3251US2021054346A1Selection methods for genetically-modified t cellsUNIV TEXAS·Filed 2020·Application pending·0 cites
- 3351US2017216358A1Methods and compositions for modification of hlaSANGAMO THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3451US2017158749A1Chimeric antigen receptors (car) and methods for making and using the sameUNIV TEXAS·Filed 2015·Application pending·0 cites
- 3550US2006018878A1Dual antigen specific T cells with trafficking abilityHOPE CITY·Filed 2005·Application pending·0 cites
- 3645US2011104128A1Device and Method for Transfecting Cells for Therapeutic UseUNIV TEXAS·Filed 2009·Application pending·0 cites
- 3745US2019351019A1Steroid administration and immunotherapyINTREXON CORP·Filed 2019·Application pending·0 cites
- 3840US2005227940A1Amplifying interfering RNA (RNAi) expression and effectsHOPE CITY·Filed 2005·Application pending·0 cites
- 3938US2017333480A1Gene modified immune effector cells and engineered cells for expansion of immune effector cellsUNIV TEXAS·Filed 2015·Application pending·0 cites
- 4038US2012321666A1T cell therapy for b cell lymphomaCOOPER LAURENCE J N·Filed 2012·Application pending·0 cites
- 4136US11059879B2Chimeric antigen receptor molecules and uses thereofUNIV TEXAS·Filed 2016·Granted Jul 13, 2021·0 cites·16 claims
- 4233US2018243340A1Combination therapy combining car + t cells with appropriately timed immunodulatory antibodiesUNIV HOUSTON SYSTEM·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Laurence J.N. Cooper files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →